Navigation Links
Most developing countries ill-equipped to ensure global biosafety: UN University

A two-year UN study of internationally funded training programmes in biotechnology and biosafety warns that as many as 100 developing countries are unprepared to effectively manage and monitor the use of modern biotechnologies, leaving the world community open to serious biosafety threats.

The report, from the United Nations University Institute of Advanced Studies, says training and management deficiencies in most countries of Africa, Central Asia, Oceania and the Caribbean, are so pervasive and broad that there is no effective international system of biosafety at the moment.

In addition, the global resources available from donor countries and agencies, already inadequate to help developing countries meet basic international agreement obligations, are being cut back. It is estimated that, over the past 15 years, just $135 million has been invested globally by public and private sources in capacity building in developing country.

The UNU-IAS assessment, released at this months Conference of Parties to the Convention on Biological Diversity in Bonn, takes no sides on genetically modified organisms and other biotech-related controversies. It was designed simply to shed a neutral, independent and objective light on international biotechnology and biosafety training programmes intended to allow developing countries to make and implement informed choices.

Among other questions examined:

  • Are current capacity building initiatives directed towards particular policy or regulatory outcomes?

  • Do they drive the policy process in developing countries?

  • Are capacity building initiatives in biosafety and biotech demand driven?

  • How can integrated capacity building be provided given lack of international consensus about nature and extent of risks posed by Living Modified Organisms?

  • Are regional approaches appropriate for capacity building in biosafety and biotech?

  • Is there sufficient donor coordination to avoid inappropriate duplication?

  • Are existing activities sustainable?

  • How should capacity building differentiate between developing countries at different stages of uptake of modern biotech?

  • How can capacity building gaps and problems be addressed?

Authors, Sam Johnston, Catherine Monagle, Jessica Green and Ruth Mackenzie say the use and prevalence of biotechnology in agriculture and other sectors seems certain to increase. And the widespread ratification of the worlds Cartagena Protocol on Biosafety (CPB), which will mark the 5th anniversary of its coming into force on Sept. 11, 2008, demonstrates the desire for biosafety measures to go hand in hand with the development of biotechnology.

However, they cite the lack of technical, policy and enforcement capacities in developing countries as a potentially contributing factor to the spread of bioterrorism -- the deliberate release of naturally-occurring or human-modified bacteria, viruses, toxins or other biological agents.

Among other points and observations:

  • Globalization, resulting in the increasing flow of information, people and resources, has weakened the power of states to manage technology development and will make it harder to develop an effective international regime;

  • The lack of capacities and the associated policy vacuum allow for vested interests to predominate, dampen support for research and create hesitation on the part of governments to properly engage with the issue;

  • A country that lacks capacity is more likely to bring in very restrictive systems in order to counterbalance its deficiencies and undermines their ability to consider less contentious uses of biotechnology, such as in diagnostics, industrial enzymes, pollution remediation, combating drought and reversing salinity;

  • The lack of capacity creates dependency in developing countries;

  • The use of genetically-modified crops in many developing countries makes future trade bans and disruption likely;

  • The lack of an effective biosafety regime undermines the potential for developing countries to consider the role of biotechnology in critical areas such as addressing climate change.

Most available capacity building resources to date have been devoted to developing policy and regulatory regimes, including approval procedures and risk assessment. Scientific training has focused mostly on risk assessment and, to a lesser extent, on the detection of genetically modified organisms.

The authors offer a suite of recommendations, emphasizing that capacity needs should be identified locally, not internationally, and point to success stories on which world efforts should be built.

The findings raise fundamental questions about the extent to which capacity deficits are undermining the promise that advances in biotechnology would directly address the needs of the poor, says UNU-IAS Director A.H. Zakri.

There may also be broader implications of a capacity deficit in biosafety and biotechnology. These may include an impaired ability to meet the challenges of global issues such as climate change, or to protect humans and the environment against biosecurity risks.


Contact: Terry Collins
United Nations University

Related biology technology :

1. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
2. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
3. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
4. Free CME-certified Webcast: Making Your Case: Up-to-date Answers for Developing Trends in PCI
5. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
6. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
7. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
8. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
9. Iowa State researchers developing system to efficiently convert biomass to ethanol
10. Pharmaceuticals & Biotechs to Share Insights for Developing Leaders in a Fast-Paced, Competitive Industry
11. Developing Sales Leaders: Benchmarks Reveal Tactics that Will Propel Your Business
Post Your Comments:
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... . The Global ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):